Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Moik, F; Prager, G; Thaler, J; Posch, F; Wiedemann, S; Schramm, T; Englisch, C; Mackman, N; Pabinger, I; Ay, C.
Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
Arterioscler Thromb Vasc Biol. 2021; 41(11): 2837-2847.
Doi: 10.1161/ATVBAHA.121.316463
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
-
Moik Florian
- Co-authors Med Uni Graz
-
Posch Florian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective: Pancreatic cancer activates coagulation and increases risk of venous thromboembolism (VTE). We aimed at characterizing the association of hemostatic biomarkers and VTE with mortality and chemotherapy response. Approach and Results: Pancreatic cancer patients (N=145) were included in a prospective, observational cohort study (CATS [Vienna Cancer and Thrombosis Study]). Hemostatic biomarkers (D-dimer, extracellular vesicle-tissue factor activity, prothrombin fragment 1+2, fibrinogen, factor VIII, PAI-1 [plasminogen activator inhibitor 1], sP-selectin [soluble P-selectin], thrombin generation assay) were measured at inclusion. The impact of VTE on overall survival/progression-free survival (OS/PFS) was evaluated by multistate modeling. The association of biomarkers with OS was analyzed by Cox-regression and with PFS and disease control rate in patients initiating palliative chemotherapy (n=95) by Cox-regression and logistic regression. Multivariable analysis included stage, grade, sex, age, performance status, VTE (time-dependent), vascular infiltration/compression, and tumor marker levels (carbohydrate-antigen 19-9, carcinoembryonic antigen). VTE occurrence was associated with shorter OS (transition hazard ratio, 3.40 [95% CI, 2.05-5.64]) and shorter PFS (transition hazard ratio, 2.10 [1.16-3.79]). Median post-VTE OS/PFS in months was 5.5 [2.2-6.5] and 3.0 [1.5-3.9], compared with 13.4 [9.7-16.6] and 7.5 [5.9-9.8] in patients without VTE (both P<0.001). D-dimer, extracellular vesicle-tissue factor activity, PAI-1, and sP-selectin were associated with increased mortality (hazard ratio per doubling, 1.27 [1.00-1.61]; 1.63 [1.14-2.36]; 1.25 [1.06-1.47]; 1.52 [1.05-2.20]). In patients initiating palliative chemotherapy, higher D-dimer predicted shorter PFS (hazard ratio per doubling, 1.27 [1.01-1.60]) and lower disease control rate (odds ratio per doubling, 0.59 [0.36-0.98]). Conclusions: VTE diagnosis is associated with shorter OS and PFS. Higher baseline levels of D-dimer, extracellular vesicle-tissue factor activity, PAI-1, and sP-selectin were independently prognostic for increased mortality, and D-dimer predicted response to palliative chemotherapy.
- Find related publications in this database (using NLM MeSH Indexing)
-
Aged - administration & dosage
-
Anticoagulants - therapeutic use
-
Antineoplastic Agents - adverse effects, therapeutic use
-
Biomarkers - blood
-
Disease Progression - administration & dosage
-
Extracellular Vesicles - metabolism
-
Female - administration & dosage
-
Fibrin Fibrinogen Degradation Products - metabolism
-
Hemostasis - administration & dosage
-
Humans - administration & dosage
-
Incidence - administration & dosage
-
Male - administration & dosage
-
Middle Aged - administration & dosage
-
P-Selectin - blood
-
Pancreatic Neoplasms - blood, diagnosis, drug therapy, mortality
-
Plasminogen Activator Inhibitor 1 - blood
-
Progression-Free Survival - administration & dosage
-
Prospective Studies - administration & dosage
-
Risk Assessment - administration & dosage
-
Risk Factors - administration & dosage
-
Thromboplastin - metabolism
-
Time Factors - administration & dosage
-
Treatment Outcome - administration & dosage
-
Venous Thromboembolism - blood, diagnosis, drug therapy, mortality
- Find related publications in this database (Keywords)
-
biomarkers
-
hemostasis
-
mortality
-
neoplasms
-
venous thromboembolism